Condition

Lung Cancer Non-small Cell Stage IV

ClinicalTrials.gov condition label

Clinical trials9

Recruiting0

Common interventions14

Lead sponsors shown8

Clinical trials

9 shown

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung CancerNCT06555263 · 2024-08-21

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerNCT06463171 · 2024-06-01

Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung CancerNCT05127382 · 2020-02-01

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLCNCT03769103 · 2019-03-19

ACTIVE_NOT_RECRUITING

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC PatientsNCT04184921 · 2019-01-01

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung CancerNCT03866993 · 2018-12-20

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerNCT03866980 · 2018-11-27

Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip PlatformNCT03692442 · 2018-05-01

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapyNCT02129699 · 2015-01-06

Common interventions

AK105BIOLOGICAL2 carboplatinDRUG2 placeboDRUG2 AlmonertinibDRUG1 AnlotinibDRUG1 Aspirin 100mgDRUG1 DenosumabDRUG1 Luveltamab tazevibulinDRUG1 None, standard chemotherapy onlyOTHER1 OsimertinibDRUG1 Osimertinib 80 MGDRUG1 PaclitaxelDRUG1 pemetrexedDRUG1 Stereotactic radiotherapyRADIATION1

Leading sponsors

Akeso2 British Columbia Cancer Agency1 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University1 ETOP IBCSG Partners Foundation1 Guangzhou Institute of Respiratory Disease1 Hellenic Cooperative Oncology Group1 Shanghai Pulmonary Hospital, Shanghai, China1 Sutro Biopharma, Inc.1

Trial status mix

UNKNOWN3

COMPLETED2

TERMINATED2

ACTIVE_NOT_RECRUITING1

WITHDRAWN1

Phase mix

PHASE24

PHASE33

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.